HanAll BioPharma Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1973-11-20
- Employees
- -
- Market Cap
- -
- Website
- http://www.hanall.co.kr
A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects
Phase 1
Completed
- Conditions
- HypertensionHyperlipidemia
- Interventions
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01806324
Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis
Phase 2
Completed
- Conditions
- Mild to Moderate Atopic Dermatitis
- Interventions
- Drug: HL-009 Liposomal GelDrug: Placebo
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01568489
Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
Phase 3
Completed
- Conditions
- Essential HypertensionHyperlipidemia
- Interventions
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 356
- Registration Number
- NCT01541943
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01511874
- Locations
- 🇰🇷
Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2012-10-16
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01440686
- Locations
- 🇰🇷
Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute, Seoul, Korea, Republic of
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
Phase 1
Completed
- Conditions
- Chronic Hepatitis C InfectionGenotype 1
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01194037
© Copyright 2025. All Rights Reserved by MedPath